https://www.pharmaceutical-technology.com/data-insights/spesolimab-boehringer-ingelheim-international-netherton-syndrome-trichorrhexis-invaginata-bamboo-hair-likelihood-of-approval/
Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata,...
boehringer ingelheimnetherton syndrometrichorrhexis invaginataspesolimabinternational